Pretreatment with WAY-100635 differentially affects the ability of maximally effective doses of 5-HT2A/2C antagonists, mixed 5-HT1A agonist/5-HT2A/2C antagonists and 5-HT1Aagonists to inhibit DOI-induced head twitches
| Treatment | Saline + MED5-a | WAY-100635 + MED | |||
|---|---|---|---|---|---|
| MED | Head twitches | Head twitches | |||
| mg/kg | Mean ± S.E. | %5-b | Mean ± S.E. | %5-b | |
| Ritanserin | 0.16 | 0 ± 0 | 0 | 0 ± 0 | 0c |
| Ketanserin | 0.63 | 0 ± 0 | 0 | 0 ± 0 | 0c |
| 8-OH-DPAT | 2.5 | 0.11 ± 0.12 | 11 | 2.0 ± 0.58 | 86d |
| Buspirone | 2.5 | 0 ± 0 | 0 | 1.3 ± 0.39 | 71d |
| FG5974 | 2.5 | 0.14 ± 0.15 | 14 | 1.2 ± 0.60 | 57d |
| WY-50,324 | 2.5 | 0.11 ± 0.12 | 11 | 0.71 ± 0.36 | 43d |
| LEK-8804 | 2.5 | 0 ± 0 | 0 | 0.43 ± 0.42 | 29d |
| CGS 18102A | 10 | 0 ± 0 | 0 | 0 ± 0 | 0c |
↵5-a MED, Maximally effective dose; dose-producing inhibition of head twitches in more than 85% of animals tested.
↵5-b Percentage of animals (n = 7 to 9/dose) showing one or more head twitches during the 10-min observation period.
c,d Values not sharing the same letter are significantly different from each other (P < .05).